Mark Sculpher
Names
| first: |
Mark |
| last: |
Sculpher |
Identifer
Contact
Research profile
author of:
- Country-level cost-effectiveness thresholds: initial estimates and the need for further research (RePEc:chy:respap:109cherp)
by Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton - Supporting the development of an essential health package: principles and initial assessment for Malawi (RePEc:chy:respap:136cherp)
by Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger - Scoping review on social care economic evaluation methods (RePEc:chy:respap:150cherp)
by Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards - A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis (RePEc:chy:respap:169chedp)
by Mark Sculpher & David Torgerson & Ron Goeree & Bernie O'Brien - Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling (RePEc:chy:respap:179chedp)
by Elizabeth Fenwick & Karl Claxton & Mark Sculpher & Andrew Briggs - Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions (RePEc:chy:respap:31cherp)
by Karl Claxton & Mark Sculpher & Tony Culyer - Appropriate Perspectives for Health Care Decisions (RePEc:chy:respap:54cherp)
by Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher - The value of implementation and the value of information: combined and uneven development (RePEc:chy:respap:5cherp)
by Elisabeth Fenwick & Karl Claxton & Mark Sculpher - Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS (RePEc:chy:respap:60cherp)
by Karl Claxton & Mark Sculpher & Stuart Carroll - Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions (RePEc:chy:respap:77cherp)
by Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer - Methods for the estimation of the NICE cost effectiveness threshold (RePEc:chy:respap:81cherp)
by Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher - Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose? (RePEc:chy:respap:98cherp)
by Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher - Defining and characterising structural uncertainty in decision analytic models (RePEc:chy:respap:9cherp)
by Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher - Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations (RePEc:eee:hepoli:v:93:y:2009:i:2-3:p:85-92)
by Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda - Shared treatment decision making in a collectively funded health care system: possible conflicts and some potential solutions (RePEc:eee:socmed:v:54:y:2002:i:9:p:1369-1377)
by Sculpher, Mark & Gafni, Amiram & Watt, Ian - Decision-making with Uncertainty: The Value of Information (RePEc:elg:eechap:14021_51)
by Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher - Decision-making with Uncertainty: The Value of Information (RePEc:elg:eechap:3572_48)
by Karl Claxton & Elizabeth Fenwick & Mark J. Sculpher - Recognizing Preference Diversity: The Use of Preference Sub-Groups in Cost-Effectiveness Analysis (RePEc:hpa:wpaper:199901)
by M Sculpher & A Gafni - Income Effects of Reduced Health and Health Effects of Reduced Income: Implications for Health State Valuation (RePEc:hpa:wpaper:199902)
by M Sculpher & B O'Brien - Building Uncertainty into Cost-Effectiveness Rankings: Portfolio Risk-Return Trade-Offs and Implications for Decision Rules (RePEc:hpa:wpaper:199905)
by B O'Brien & M Sculpher - Productivity Costs: Principles and Practice in Economic Evaluation (RePEc:ohe:monogr:000464)
by Clive Pritchard;Martin Sculpher - Decision Modelling for Health Economic Evaluation (RePEc:oxp:obooks:9780198526629)
by Briggs, Andrew & Sculpher, Mark & Claxton, Karl - What is the Quality of Economic Evaluations of Non-Drug Therapies? A Systematic Review and Critical Appraisal of Economic Evaluations of Radiotherapy for Cancer (RePEc:spr:aphecp:v:12:y:2014:i:5:p:497-510)
by M. Barbieri & H. Weatherly & R. Ara & H. Basarir & M. Sculpher & R. Adams & H. Ahmed & C. Coles & T. Guerrero-Urbano & C. Nutting & M. Powell - An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis? (RePEc:spr:eujhec:v:11:y:2010:i:1:p:57-66)
by Rachel Elliott & Helen Weatherly & Neil Hawkins & Gillian Cranny & Duncan Chambers & Lindsey Myers & Alison Eastwood & Mark Sculpher - Estimating utility data from clinical indicators for patients with stable angina (RePEc:spr:eujhec:v:6:y:2005:i:4:p:347-353)
by Louise Longworth & Martin Buxton & Mark Sculpher & David Smith - Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy (RePEc:spr:pharme:v:17:y:2000:i:4:p:361-370)
by Mark Sculpher & Michael Palmer & Anne Heyes - Assessing Generalisability in Model-Based Economic Evaluation Studies (RePEc:spr:pharme:v:24:y:2006:i:12:p:1181-1197)
by Hege Urdahl & Andrea Manca & Mark Sculpher - A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD (RePEc:spr:pharme:v:25:y:2007:i:10:p:829-841)
by Laura Bojke & Edward Hornby & Mark Sculpher - Recombinant Erythropoietin for Chemotherapy-Related Anaemia (RePEc:spr:pharme:v:25:y:2007:i:3:p:223-237)
by Diego Ossa & Andrew Briggs & Emma McIntosh & Warren Cowell & Tim Littlewood & Mark Sculpher - Real Economics Needs to Reflect Real Decisions (RePEc:spr:pharme:v:30:y:2012:i:2:p:133-136)
by Mark Sculpher & Karl Claxton - Golimumab for the Treatment of Psoriatic Arthritis (RePEc:spr:pharme:v:30:y:2012:i:4:p:257-270)
by Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott - Acknowledging Patient Heterogeneity in Economic Evaluation (RePEc:spr:pharme:v:31:y:2013:i:2:p:111-123)
by Janneke Grutters & Mark Sculpher & Andrew Briggs & Johan Severens & Math Candel & James Stahl & Dirk Ruysscher & Albert Boer & Bram Ramaekers & Manuela Joore - Should the Lambda (λ) Remain Silent? (RePEc:spr:pharme:v:34:y:2016:i:4:d:10.1007_s40273-015-0359-7)
by Hossein Haji Ali Afzali & Jonathan Karnon & Mark Sculpher - Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis (RePEc:wly:hlthec:v:10:y:2001:i:4:p:317-324)
by Mark Sculpher & Amiram Gafni - Representing uncertainty: the role of cost‐effectiveness acceptability curves (RePEc:wly:hlthec:v:10:y:2001:i:8:p:779-787)
by Elisabeth Fenwick & Karl Claxton & Mark Sculpher - Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply (RePEc:wly:hlthec:v:11:y:2002:i:7:p:653-654)
by Mark Sculpher & Amiram Gafni - Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra (RePEc:wly:hlthec:v:14:y:2005:i:4:p:339-347)
by Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan - Assessing generalisability by location in trial‐based cost‐effectiveness analysis: the use of multilevel models (RePEc:wly:hlthec:v:14:y:2005:i:5:p:471-485)
by Andrea Manca & Nigel Rice & Mark J. Sculpher & Andrew H. Briggs - Estimating mean QALYs in trial‐based cost‐effectiveness analysis: the importance of controlling for baseline utility (RePEc:wly:hlthec:v:14:y:2005:i:5:p:487-496)
by Andrea Manca & Neil Hawkins & Mark J. Sculpher - Discounting and cost‐effectiveness in NICE – stepping back to sort out a confusion (RePEc:wly:hlthec:v:15:y:2006:i:1:p:1-4)
by Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier - Evidence synthesis, parameter correlation and probabilistic sensitivity analysis (RePEc:wly:hlthec:v:15:y:2006:i:4:p:373-381)
by A. E. Ades & Karl Claxton & Mark Sculpher - Whither trial‐based economic evaluation for health care decision making? (RePEc:wly:hlthec:v:15:y:2006:i:7:p:677-687)
by Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe - Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods (RePEc:wly:hlthec:v:19:y:2010:i:10:p:1132-1136)
by Mark Sculpher & Karl Claxton - Dangerous omissions: the consequences of ignoring decision uncertainty (RePEc:wly:hlthec:v:20:y:2011:i:2:p:212-224)
by Susan C. Griffin & Karl P. Claxton & Stephen J. Palmer & Mark J. Sculpher - Causes For Concern: Is Nice Failing To Uphold Its Responsibilities To All Nhs Patients? (RePEc:wly:hlthec:v:24:y:2015:i:1:p:1-7)
by Karl Claxton & Mark Sculpher & Stephen Palmer & Anthony J Culyer - Social value and individual choice: The value of a choice‐based decision‐making process in a collectively funded health system (RePEc:wly:hlthec:v:27:y:2018:i:2:p:e28-e40)
by Manuel Antonio Espinoza & Andrea Manca & Karl Claxton & Mark Sculpher - How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework (RePEc:wly:hlthec:v:27:y:2018:i:2:p:e41-e54)
by Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo - Sensitivity analysis in economic evaluation: A review of published studies (RePEc:wly:hlthec:v:4:y:1995:i:5:p:355-371)
by Andrew Briggs & Mark Sculpher - The cost‐effectiveness of preference‐based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia (RePEc:wly:hlthec:v:7:y:1998:i:2:p:129-142)
by Mark Sculpher - Economic Evaluation in Health Care Research and Development: Undertake it Early and Often (RePEc:wuk:hergdp:0012)
by Mark Sculpher & Michael Drummond & Martin Buxton - Antenatal testing for HIV Infection: Developing a Model for Economic Evaluation (RePEc:wuk:hergdp:0014)
by Andrew Briggs & Diana Gibb & Mark Sculpher & Sandra MacDonagh & Tony Ades